A longitudinal multimodal neuroimaging study investigating the dopamine transporter, nigral neuromelanin, and quantitative susceptibility mapping in RBD and PD aimed to track neurodegenerative changes over time and better understand the progression from RBD to PD. This evidence concerns the gene SLC6A3 and Parkinson disease.